{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T00:15:08Z","timestamp":1788567308718,"version":"build-2803163510"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,22]],"date-time":"2024-12-22T00:00:00Z","timestamp":1734825600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002347","name":"Bundesministerium f\u00fcr Bildung und Forschung","doi-asserted-by":"publisher","award":["01ZZ1804B"],"award-info":[{"award-number":["01ZZ1804B"]}],"id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002347","name":"Bundesministerium f\u00fcr Bildung und Forschung","doi-asserted-by":"publisher","award":["01ZZ1804C"],"award-info":[{"award-number":["01ZZ1804C"]}],"id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.msard.2024.106247","type":"journal-article","created":{"date-parts":[[2024,12,21]],"date-time":"2024-12-21T11:35:57Z","timestamp":1734780957000},"page":"106247","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Multivariable prognostic prediction of efficacy and safety outcomes and response to fingolimod in people with relapsing-remitting multiple sclerosis"],"prefix":"10.1016","volume":"93","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9008-0141","authenticated-orcid":false,"given":"Beg\u00fcm","family":"Irmak \u00d6n","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joachim","family":"Havla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich","family":"Mansmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.msard.2024.106247_bib0001","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.neuron.2018.01.021","article-title":"Multiple sclerosis: mechanisms and immunotherapy","volume":"97","author":"Baecher-Allan","year":"2018","journal-title":"Neuron"},{"issue":"8","key":"10.1016\/j.msard.2024.106247_bib0002","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1177\/0272989X18801312","article-title":"A tutorial on evaluating the time-varying discrimination accuracy of survival models used in dynamic decision making","volume":"38","author":"Bansal","year":"2018","journal-title":"Med. Decis. Making"},{"issue":"3","key":"10.1016\/j.msard.2024.106247_bib0003","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1097\/00019052-200206000-00003","article-title":"The clinico-radiological paradox in multiple sclerosis revisited","volume":"15","author":"Barkhof","year":"2002","journal-title":"Curr. Opin. Neurol."},{"issue":"5","key":"10.1016\/j.msard.2024.106247_bib0004","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0233575","article-title":"Systematic review of prediction models in relapsing remitting multiple sclerosis","volume":"15","author":"Brown","year":"2020","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.msard.2024.106247_bib0005","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/S1474-4422(14)70049-3","article-title":"Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial","volume":"13","author":"Calabresi","year":"2014","journal-title":"Lancet Neurol"},{"issue":"1","key":"10.1016\/j.msard.2024.106247_bib0007","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s41512-021-00106-6","article-title":"Development, validation and clinical usefulness of a prognostic model for relapse in relapsing-remitting multiple sclerosis","volume":"5","author":"Chalkou","year":"2021","journal-title":"Diagn. Progn. Res."},{"issue":"20","key":"10.1016\/j.msard.2024.106247_bib0008","doi-asserted-by":"crossref","first-page":"4362","DOI":"10.1002\/sim.9034","article-title":"A two-stage prediction model for heterogeneous effects of treatments","volume":"40","author":"Chalkou","year":"2021","journal-title":"Stat. Med."},{"issue":"3","key":"10.1016\/j.msard.2024.106247_bib0009","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1177\/0272989X221143058","article-title":"Decision curve analysis for personalized treatment choice between multiple options","volume":"43","author":"Chalkou","year":"2023","journal-title":"Med. Decis. Making"},{"key":"10.1016\/j.msard.2024.106247_bib0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.cmpb.2021.106180","article-title":"Longitudinal machine learning modeling of MS patient trajectories improves predictions of disability progression","volume":"208","author":"De Brouwer","year":"2021","journal-title":"Comput. Methods Programs Biomed."},{"key":"10.1016\/j.msard.2024.106247_bib0011","doi-asserted-by":"crossref","DOI":"10.1016\/j.cmpb.2021.106479","article-title":"Corrigendum to longitudinal machine learning modeling of MS patient trajectories improves predictions of disability progression: [Computer Methods and Programs in Biomedicine, Volume 208, (September 2021) 106180]","volume":"213","author":"De Brouwer","year":"2022","journal-title":"Comput. Methods Programs Biomed"},{"key":"10.1016\/j.msard.2024.106247_bib0012","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.msard.2016.05.015","article-title":"Relapse rates in patients with multiple sclerosis treated with fingolimod: subgroup analyses of pooled data from three phase 3 trials","volume":"8","author":"Derfuss","year":"2016","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"5","key":"10.1016\/j.msard.2024.106247_bib0013","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/S1474-4422(12)70056-X","article-title":"Relapse and disability outcomes in patients with multiple sclerosis treated with fingolimod: subgroup analyses of the double-blind, randomised, placebo-controlled FREEDOMS study","volume":"11","author":"Devonshire","year":"2012","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.msard.2024.106247_bib0014","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.101928","article-title":"Predictive medicine in multiple sclerosis: a systematic review","volume":"40","author":"Havas","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2024.106247_bib0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.103534","article-title":"Trends in administrative prevalence of multiple sclerosis and utilization patterns of disease modifying drugs in Germany","volume":"59","author":"Holstiege","year":"2022","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"1","key":"10.1016\/j.msard.2024.106247_bib0016","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1515\/ijb-2012-0052","article-title":"An approach to evaluating and comparing biomarkers for patient treatment selection","volume":"10","author":"Janes","year":"2014","journal-title":"Int. J. Biostat."},{"issue":"5","key":"10.1016\/j.msard.2024.106247_bib0017","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1056\/NEJMoa0909494","article-title":"A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis","volume":"362","author":"Kappos","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.msard.2024.106247_bib0018","article-title":"Personalized evidence based medicine: predictive approaches to heterogeneous treatment effects","volume":"363","author":"Kent","year":"2018","journal-title":"BMJ"},{"issue":"1","key":"10.1016\/j.msard.2024.106247_bib0019","doi-asserted-by":"crossref","first-page":"W1","DOI":"10.7326\/M18-1377","article-title":"PROBAST: A tool to assess risk of bias and applicability of prediction model studies: explanation and elaboration","volume":"170","author":"Moons","year":"2019","journal-title":"Ann. Intern. Med."},{"issue":"1","key":"10.1016\/j.msard.2024.106247_bib0020","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s40120-019-00172-5","article-title":"Real-world treatment of patients with multiple sclerosis per MS subtype and associated healthcare resource use: an analysis based on 13,333 patients in Germany","volume":"9","author":"M\u00fcller","year":"2020","journal-title":"Neurol. Ther."},{"issue":"5","key":"10.1016\/j.msard.2024.106247_bib0021","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0231846","article-title":"Epidemiology, characteristics and treatment of patients with relapsing remitting multiple sclerosis and incidence of high disease activity: Real world evidence based on German claims data","volume":"15","author":"Ohlmeier","year":"2020","journal-title":"PLoS One"},{"issue":"9","key":"10.1016\/j.msard.2024.106247_bib0022","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1177\/1352458519849513","article-title":"A proof-of-concept application of a novel scoring approach for personalized medicine in multiple sclerosis","volume":"26","author":"Pellegrini","year":"2020","journal-title":"Mult. Scler."},{"issue":"14","key":"10.1016\/j.msard.2024.106247_bib0023","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1177\/1352458519887343","article-title":"Predicting disability progression in multiple sclerosis: insights from advanced statistical modeling","volume":"26","author":"Pellegrini","year":"2020","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2024.106247_bib0024","author":"Reeve","year":"2023","journal-title":"Prognostic models for predicting clinical disease progression, worsening and activity in people with multiple sclerosis"},{"key":"10.1016\/j.msard.2024.106247_bib0025","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1186\/s12874-020-01145-1","article-title":"Predictive approaches to heterogeneous treatment effects: a scoping review","volume":"20","author":"Rekkas","year":"2020","journal-title":"BMC Med. Res. Methodol."},{"issue":"1","key":"10.1016\/j.msard.2024.106247_bib0026","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1515\/ijb-2015-0032","article-title":"Model-based recursive partitioning for subgroup analyses","volume":"12","author":"Seibold","year":"2016","journal-title":"Int. J. Biostat."},{"issue":"7733","key":"10.1016\/j.msard.2024.106247_bib0027","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1038\/d41586-018-07535-2","article-title":"Statistical pitfalls of personalized medicine","volume":"563","author":"Senn","year":"2018","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.msard.2024.106247_bib0028","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1001381","article-title":"Prognosis research strategy (PROGRESS) 3: prognostic model research","volume":"10","author":"Steyerberg","year":"2013","journal-title":"PLoS Med"},{"issue":"1","key":"10.1016\/j.msard.2024.106247_bib0029","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s12874-020-0906-6","article-title":"Framework for personalized prediction of treatment response in relapsing remitting multiple sclerosis","volume":"20","author":"St\u00fchler","year":"2020","journal-title":"BMC Med. Res. Methodol."},{"issue":"2","key":"10.1016\/j.msard.2024.106247_bib0030","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1038\/nrneurol.2016.188","article-title":"Treatment decisions in multiple sclerosis \u2014 insights from real-world observational studies","volume":"13","author":"Trojano","year":"2017","journal-title":"Nat. Rev. Neurol."},{"issue":"21","key":"10.1016\/j.msard.2024.106247_bib0031","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1056\/NEJMsr077003","article-title":"Statistics in medicine \u2014 reporting of subgroup analyses in clinical trials","volume":"357","author":"Wang","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.msard.2024.106247_bib0032","article-title":"Multiple sclerosis therapy consensus group (MSTCG): position statement on disease-modifying therapies for multiple sclerosis (white paper). Ther","volume":"14","author":"Wiendl","year":"2021","journal-title":"Adv. Neurol. Disord."},{"issue":"4","key":"10.1016\/j.msard.2024.106247_bib0033","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/nrneurol.2016.21","article-title":"Disease-modifying therapies and infectious risks in multiple sclerosis","volume":"12","author":"Winkelmann","year":"2016","journal-title":"Nat. Rev. Neurol."},{"issue":"1","key":"10.1016\/j.msard.2024.106247_bib0034","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1186\/s12974-019-1674-2","article-title":"Molecular biomarkers in multiple sclerosis","volume":"16","author":"Ziemssen","year":"2019","journal-title":"J. Neuroinflammation"}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221103482400823X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221103482400823X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T10:29:39Z","timestamp":1778840979000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S221103482400823X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":33,"alternative-id":["S221103482400823X"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2024.106247","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Multivariable prognostic prediction of efficacy and safety outcomes and response to fingolimod in people with relapsing-remitting multiple sclerosis","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2024.106247","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"106247"}}